Sep 04, 2020 The US Food and Drug Administration has issued a warning letter to Mylan Laboratories Limited's plant in Telangana for significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API). USFDA in their letter dated…
Recent Post
- CDSCO Issues Public Notice on Disposal of Long-Pending SUGAM Applications
- India Bans High-Dose Nimesulide: What You Need to Know
- Compounding of Offences under the Drugs and Cosmetics Act, 1940: What Stakeholders Need to Know
- 🚨 CDSCO Directive on Immediate Inspections as per Revised Schedule M – Is Your Facility Ready?
- CDSCO Issues Regulatory Clarification on Combi-Pack Approvals: Key Insights for Injectable Manufacturers
